Breast Cancer

Lynparza Slows Spread of Inherited Breast Cancer Caused by BRCA Mutations: First Drug Approved for BRCA Breast Cancer (01-15-2018)

CancerConnect News: The US Food and Drug Administration (FDA) has extended the approval of Lynparza (olaparib) to include the treatment of metastatic breast cancer in patients who carry the specific inherited BRCA mutation.  These patients can be identified... Continue Reading

Updated Keytruda®/Halaven® Report Encouraging for Treatment of Triple Negative Breast Cancer (01-10-2018)

CancerConnect News: The investigative treatment combination including Keytruda® (pembrolizumab) plus Halaven® (eribulin) could provide a potential therapeutic option for patients with advanced triple-negative breast cancer (TNBC) whose disease has advanced... Continue Reading

Start 2018 Right: Plan for Cancer Screening and Save Lives! (01-5-2018)

Screening guidelines should initiate conversations with your healthcare team.  Charles H Weaver MD, Editor CancerConnect CancerConnect News: The goal of cancer screening is to find disease at early stages in people who are otherwise asymptomatic—before... Continue Reading

Oral Contraceptive Use Still Linked to Breast Cancer (12-27-2017)

Women who rely on birth control pills or contraceptive devices that release hormones face a small but significant increase in the risk for breast cancer, according to a large study published in the New England Journal of Medicine.1 This study is the first... Continue Reading

Acupuncture Reduces Aromatase Inhibitor Joint Pain in Women with Breast Cancer (12-14-2017)

According to a well designed study presented at the 2017 San Antonio Breast Cancer Symposium acupuncture is effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.1 Stiffness and... Continue Reading

Kisqali® Improves Outcomes of Premenopausal Women with HR+/HER2- Advanced Breast Cancer (12-12-2017)

It was announced today that results from the Phase III MONALEESA-7 trial evaluating Kisqali® (ribociclib) in combination endocrine-based therapy in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2... Continue Reading

Keytruda Immunotherapy Shows Promise for Patients With Herceptin-resistant Breast Cancer (12-12-2017)

A combination of Keytruda (pembrolizumab) and Herceptin (trastuzumab), tested in patients with Herceptin-resistant advanced HER2-positive breast cancer, was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker... Continue Reading

Kisqali® Improves Outcomes for Premenopausal Women with HR+/HER2- Advanced Breast Cancer (11-14-2017)

Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old.1,2 ,3 Historically there younger women were treated the same as their... Continue Reading

Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer (11-1-2017)

Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy (ExteNET trial) were presented at the European Society of Medical Oncology... Continue Reading

Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer (10-30-2017)

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer... Continue Reading

Next Page »